Previous corticosteroid exposure associates with an increased Pneumocystis jirovecii pneumonia mortality among HIV-negative patients: a global research network with a follow-up multicenter case-control study.
Lilian Vargas BarahonaKyle C MolinaLaura C Pedraza-ArévaloStefan SillauAlex TagawaSias SchergerDaniel B ChastainLeland ShapiroJose TuellsCarlos Franco-ParedesKellie L HawkinsJames P MaloneyGeorge R ThompsonAndrés F Henao MartinezPublished in: Therapeutic advances in infectious disease (2023)
Preceding corticosteroids in HIV-negative patients with PJP are associated with higher mortality. A higher fungal burden may influence corticosteroid-mediated mortality. Assessment of PJP prophylaxis must become a standard clinical best practice when instituting corticosteroid therapy courses.
Keyphrases
- antiretroviral therapy
- cardiovascular events
- hiv positive
- hiv infected
- end stage renal disease
- human immunodeficiency virus
- hiv testing
- risk factors
- hepatitis c virus
- chronic kidney disease
- newly diagnosed
- hiv aids
- ejection fraction
- healthcare
- primary care
- men who have sex with men
- peritoneal dialysis
- cardiovascular disease
- stem cells
- coronary artery disease
- type diabetes
- mesenchymal stem cells
- patient reported outcomes
- smoking cessation
- network analysis